2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1384

The Frequency of Non-Radiographic Axial Spondyloarthritis in Relation to Symptom Duration in Patients Referred Because of Chronic Back Pain: Results From the Berlin Early Spondyloarthritis Clinic
Abstract Number: 754

The Functional Index-3 in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance
Abstract Number: 994

The Genome-Wide Expression of Human Osteoarthritic Cartilage Shows A Differential Pattern Between Two Subgroups of OA Patients
Abstract Number: 1446

The Granulocyte Signature and Organ Inflammation in TLR7 Responsive Mice Is RNA and Type 1 Interferon Dependent
Abstract Number: 2688

The Health Improvement and Prevention Program in Systemic Lupus Erythematosus Demonstrates Improvement in Mental Health and Framingham Risk Score At One Year
Abstract Number: 1328

The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Abstract Number: 2294

The Histone Deacetylase SIRT1 Is Anti-Fibrotic and Mediates Resveratrol Effects
Abstract Number: 1936

The Human Leukocyte Antigen DRB1*13:02-DQB1*06:04-DPB1*04:01 Haplotype Is Closely Associated with Dermatomyositis Patients with Anti-CADM-140 (Melanoma Differentiation-Associated Protein 5: MDA5) Antibody
Abstract Number: 407

The I50V IL4R SNP Is Associated with Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis
Abstract Number: 1005

The Identification of Pathway Markers in Behcet’s Disease Using Genomewide Association Data From Two Different Populations
Abstract Number: 546

The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients
Abstract Number: 764

The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2413

The Impact of Asymptomatic Vertebral Fractures On Quality of Life in Community-Dwelling Older Women: The Sao Paulo Ageing & Health Study (SPAH)
Abstract Number: 947

The Impact of Dyspigmentation and Scarring in Cutaneous Lupus On Quality of Life
Abstract Number: 175

The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].